A 43-year-old woman with a 6-year history of obesity and type 2 diabetes mellitus presents to her primary care physician for a routine follow-up. Her current medications include metformin 1000 mg twice daily, but her glycemic control remains suboptimal. Her HbA1c is 8.9%, fasting glucose is 187 mg/dL, and her BMI is 36 kg/m². Blood pressure is 138/86 mmHg and heart rate is 82 bpm. Physical examination reveals central adiposity with no peripheral edema. She expresses a strong desire for a medication that can improve glycemic control while also promoting weight loss, and she is comfortable with injectable therapy. Her physician starts a once-weekly injectable drug that increases glucose-dependent insulin secretion, decreases glucagon release, and slows gastric emptying. Which of the following drugs was most likely prescribed?

1. A)Sitagliptin
2. B)SemaglutideGABARITO
3. C)Pramlintide
4. D)Glyburide
5. E)Metformin